Analyses of Bone Marrow and Blood Samples From Healthy Volunteers: Focus on the redOx Metabolism
HEALTHOX
1 other identifier
interventional
102
1 country
1
Brief Summary
Oxidative stress is defined by an excess of reactive oxygen species (reactive oxygen species or ROS) in cells. ROS are essential to cell life (proliferation, differentiation), including kinase activity via inhibition of phosphatases. Very low levels of ROS are observed in quiescent cells, including hematopoietic stem cells. Conversely, an excess of ROS can induce DNA damage that may lead to the destruction of the cell. The level of ROS in cells is the result of production (mainly the NADPHoxydase and the mitochondrial respiratory chain) and their disposal via antioxidant enzymes. The hematology team of the university hospital of Tours (France) found that certain antioxidant enzymes are essential for the self-renewal of normal and leukemic cells such as glutathione peroxidase-3 (Herault O et al, J Exp Med 2012, 209:895). Their expression is modified in hematological diseases (patent WO2012085188A1 / 2012-06-28 and FR1000267310 / 2014-11-27). Age potentially affects the level of expression of antioxidant genes, since it was established a decrease in glutathione peroxidase activity in women over 65 years (Sara E, J Gerontol A Biol Sci Med Sci 2008 63: 505). The study HEALTHOX will determine the impact of age on the oxidative metabolism of normal hematopoietic cells, and in particular the expression of antioxidant genes. It will provide a reference for analyzing disturbances of oxidative metabolism in blood diseases. The main objective is the comparison of peripheral blood and bone marrow cells depending from 3 groups of healthy volunteers: 18-39 years, 40-59 years and 60-85 years. The level of ROS and the expression of genes encoding the major antioxidant enzymes involved in the regulation of oxidative stress will be studied. The secondary objectives are to create a cell bank (blood and marrow), a blood plasma bank and a cDNA library (blood and marrow) from healthy volunteers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Aug 2016
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 30, 2016
CompletedFirst Posted
Study publicly available on registry
June 3, 2016
CompletedStudy Start
First participant enrolled
August 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2017
CompletedDecember 30, 2025
December 1, 2025
1 year
May 30, 2016
December 23, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Number of oxygene reactive species
Number of oxygene reactive species by flow cytometry
12 months
Study Arms (1)
Healthy volunteer
EXPERIMENTALBlood test Medullar test
Interventions
Eligibility Criteria
You may qualify if:
- Healthy volunteers
- Age ≥ 18 years old and ≤ 85 ans
- Informed and written consent
- Affiliation to Social Security
You may not qualify if:
- Subject with an history of hematologic disease
- Subject with an history of tumoral disease with chemotherapy or radiotherapy
- Subject with an history of infectious or inflammatory disease
- Subject taking a treatment in prevention of blood clots
- Subject under guardianship or protection measure
- Subject with in the last 30 days food supplement rich in antioxidant : ascorbic acid, trace elements, etc…
- Subject with in the last 30 days treatment with known effect on oxydative metabolism : N-Acetyl-Cysteine, etc…
- Participant to a drug study
- Pregnant woman
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHRU Tours
Tours, 37044, France
Related Publications (1)
Guermouche H, Ravalet N, Gallay N, Deswarte C, Foucault A, Beaud J, Rault E, Saindoy E, Lachot S, Martignoles JA, Gissot V, Suner L, Gyan E, Delhommeau F, Herault O, Hirsch P. High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers. Blood Adv. 2020 Aug 11;4(15):3550-3557. doi: 10.1182/bloodadvances.2020001582.
PMID: 32761230RESULT
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Olivier HERAULT, PhD
CHRU TOURS
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 30, 2016
First Posted
June 3, 2016
Study Start
August 1, 2016
Primary Completion
August 1, 2017
Study Completion
August 1, 2017
Last Updated
December 30, 2025
Record last verified: 2025-12